US20020022676A1 - Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol) - Google Patents

Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol) Download PDF

Info

Publication number
US20020022676A1
US20020022676A1 US09/550,372 US55037200A US2002022676A1 US 20020022676 A1 US20020022676 A1 US 20020022676A1 US 55037200 A US55037200 A US 55037200A US 2002022676 A1 US2002022676 A1 US 2002022676A1
Authority
US
United States
Prior art keywords
ppf
poly
peg
dma
tcp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/550,372
Other versions
US6384105B1 (en
Inventor
Shulin He
Michael Yaszemski
Antonios Mikos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William Marsh Rice University
Original Assignee
William Marsh Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Marsh Rice University filed Critical William Marsh Rice University
Priority to US09/550,372 priority Critical patent/US6384105B1/en
Assigned to WM. MARSH RICE UNIVERSITY reassignment WM. MARSH RICE UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HE, SHULIN, MIKOS, ANTONIOS G., YASZEMSKI, MICHAEL J.
Publication of US20020022676A1 publication Critical patent/US20020022676A1/en
Application granted granted Critical
Publication of US6384105B1 publication Critical patent/US6384105B1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: RICE UNIVERSITY
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/06Unsaturated polyesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66Polyesters containing oxygen in the form of ether groups
    • C08G63/668Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/676Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91Polymers modified by chemical after-treatment
    • C08G63/914Polymers modified by chemical after-treatment derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/918Polycarboxylic acids and polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C08G81/024Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G
    • C08G81/025Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G containing polyether sequences
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/06Unsaturated polyesters
    • C08L67/07Unsaturated polyesters having terminal carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02Polyalkylene oxides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer

Definitions

  • This invention relates to a compound for replacing or reconstructing rigid or semi-rigid living tissue. More particularly, the present invention relates to compositions comprising poly(propylene fumarate) cross linked with poly(ethylene glycol) and methods for making these compositions.
  • degradable biomaterials usually serve as a scaffold to provide mechanical support and a matrix for the ingrowth of new tissue. As new tissue forms on the scaffold, the biomaterial degrades until it is entirely dissolved. The degradation products are eliminated through the body's natural pathways, such as metabolic processes.
  • biomaterials are as a temporary bone replacement. It is often desired to replace or reconstruct all or a portion of a living bone, such as when a bone has been broken or has been resected as a result of a bone tumor.
  • the missing bone can be replaced with a mechanical device, such as a pin, plate or the like, or it can be replaced with an implant that is designed to more closely resemble the original bone itself.
  • these implants comprise biodegradable polymeric compounds or parts made from such compounds. It is contemplated that bone tissue will grow back into the pores of the implant and will gradually replace the entire implant as the implant itself is gradually degraded in the in vivo environment. For obvious reasons then, such implants should be biocompatible and non-toxic.
  • Poly(propylene fumarate) is one such polymer.
  • Poly(propylene fumarate) (hereinafter “PPF”) is an unsaturated linear polyester that degrades in the presence of water into propylene glycol and fumaric acid, degradation products that are easily cleared from the human body by normal metabolic processes. Because the fumarate double bonds in PPF are reactive and cross link at low temperatures, PPF has potential to be an effective in situ polymerizable biomaterial. The high mechanical strength of cured PPF matrices and their ability to be cross linked in situ makes them especially suitable for orthopedic application. Another advantage of cured PPF matrices is that they biodegrade into non-toxic propylene glycol and fumaric acid. On the basis of these unique properties, PPF has been formulated as bone cement, an orthopaedic scaffold for bone tissue regeneration, and a drug delivery system.
  • PPF-based formulation methods have been evaluated by varying such parameters as the molecular weight of PPF and the choice of cross linking reagents.
  • U.S. Pat. No. 5,733,951 discloses a composite mixture incorporating P(PF), a cross linking monomer (N-vinyl pyrrolidone), a porogen (sodium chloride), and a particulate phase ( ⁇ -tricalcium phosphate) that can be injected or inserted into skeletal defects of irregular shape or size.
  • PPF composite formulations can include a porogen such as NaCl for initial porosity and a particulate ceramic such as ⁇ -TCP for mechanical reinforcement and increased osteoconductivity.
  • PPF composite formulations can also include a vinyl monomer such as N-vinyl pyrrolidone, which serves as a crosslinking reagent. However, because this monomer is toxic, any unreacted amount during polymerization in situ may present a problem.
  • Poly(ethylene glycol), (PEG), is a hydrophilic polyether that has received much attention for use in biomaterials because low molecular weight PEG is passively excreted by the body. PEG has also been covalently bound to polyesters in an effort to increase polyester biocompatibility.
  • the use of acrylated PEG as a nontoxic crosslinking reagent to produce polymer networks with acrylated poly(lactic acid) has been reported.
  • PPF-based polymers cross-linked with PEG have not been made.
  • the method for making would preferably include a method for controlling the mechanical properties of the resulting polymer.
  • the present invention comprises new, injectable biodegradable polymer composites based on PPF cross linked with biocompatible PEG-DMA and, if desired, ⁇ -TCP.
  • the invention further provides the ability to control the crosslinking characteristics of the polymerizing composites and the mechanical properties of cross linked composites by varying the ⁇ -TCP content and the double bond ratio of PEG-DMA/PPF.
  • the PPF/PEG-DMA networks produced according to the present invention have clinically acceptable gel times, cross-linking temperature increases of less than 2° C., and are suitable for use as injectable, biodegradable carriers for cell transplantation or drug delivery.
  • network refers to polymeric molecules that have been cross linked so as to effectively form a continuous molecule.
  • gel is sometimes used to refer to the same type of cross linked systems.
  • FIG. 1 is a schematic chemical diagram illustrating a possible reaction scheme for crosslinking of PPF with PEG-DMA
  • FIG. 2 is a plot illustrating the dependence of compressive strength at yield of PEG-DMA/PPF composites on the double bond ratio of PEG-DMA/PPF for composites incorporating ⁇ -TCP (33 wt %) and cross linked polymers without ⁇ -TCP, both dry and wet;
  • FIG. 3 is a plot illustrating the dependence of compressive modulus of PEG-DMA/PPF composites on the double bond ratio of PEG-DMA/PPF for composites incorporating ⁇ -TCP (33 wt %) and crosslinked polymers without ⁇ -TCP both tested dry and wet; and
  • FIG. 4 is a plot illustrating the water content of PEG-DMA/PPF composites incorporating ⁇ -TCP and cross linked polymers without ⁇ -TCP as a function of the double bond ratio of PEG-DMA/PPF after equilibrium in PBS.
  • the present invention includes novel PPF-based polymers and a method for making those polymers.
  • the novel polymers comprise PPF cross linked with PEG, in which the fraction of PEG can be varied to control, among other things, the crosslinking characteristics of the composites, including the maximum crosslinking temperature and the gel point, and the properties of the cross linked composites, including its compressive strength and modulus and its water holding capacity.
  • PPF is preferably prepared by the method generally described in co-pending application Ser. No. PCT/US99/07912, filed Apr. 9, 1999, and entitled “Synthesis of Poly (Proplyene Fumarate) by Acylation of Propylene Glycol in the Presence of a Proton Scavenger,” which is incorporated herein by reference. Briefly, fumaryl chloride is added to a solution of propylene glycol in methylene chloride at 0° C. under nitrogen in the presence of K 2 CO 3 . After addition of fumaryl chloride, the reaction mixture is stirred for an additional 2 hours at 0° C. and then water is added to dissolve the inorganic salt. The organic phase is separated and dried over Na 2 SO 4 . After filtration of the mixture and evaporation of the solvent, the resulting di(2-hydroxylpropyl) fumarate is converted to PPF by transesterification at 160° C. and 0.5 mm Hg.
  • the resulting polymer can be purified by solution precipitation, forming a viscous liquid.
  • Gel permeation chromatography with a differential refractometer can be used to determine polymer molecular weight distributions.
  • FIG. 1 shows a possible reaction scheme for this reaction.
  • PPF is mixed with PEG-DMA.
  • An amount of BP is dissolved in CH 2 Cl 2 and the solution is added to the PEG-DMA/PPF mixture.
  • ⁇ -TCP is added, followed by the addition of DMT under rapid stirring for 10 s.
  • a cross linked polymeric network is formed in 10 to 15 min. The light brown polymeric network can be washed with acetone and then water to remove possible unreacted monomers.
  • Fumaryl chloride (Aldrich, Milwaukee, Wis.) was purified by distillation under nitrogen atmosphere. Propylene glycol, poly(ethylene-glycol)-dimethacrylate (PEG-DMA) (of number average molecular weight 875, liquid), benzoyl peroxide (BP), anhydrous potassium carbonate, Beta-tricalcium phosphate ( ⁇ -TCP) particles (100 mesh), N,N-dimethyl-p-toluidine (DMT), and all solvents were purchased from commercial sources and used as received.
  • BP and DMT contents are 0.3 wt % and 0.15 wt %, respectively, for all formulations.
  • Fumaryl chloride was added dropwise to a solution of propylene glycol in methylene chloride at 0° C. under nitrogen in the presence of K 2 CO 3 . After addition of fumaryl chloride, the reaction mixture was stirred for an additional 2 h at 0° C. and then water was added to dissolve the inorganic salt. The organic phase was separated and dried over Na 2 SO 4 . After filtration of the mixture and evaporation of the solvent, the formed di(2-hydroxylpropyl) fumarate was converted to PPF by transesterification at 160° C. and 0.5 mm Hg. The produced polymer was purified by solution precipitation forming a viscous liquid.
  • the temperature profile was recorded throughout the crosslinking process in a glass vial of 10 mm diameter and 24 mm length immersed into a 37° C. static water bath.
  • the crosslinking mixture was placed in the glass vial and a thermocouple was inserted to half the depth of the vial. The temperature was measured every minute until it dropped to 37° C. and the maximum temperature was recorded.
  • the gel point corresponding to the onset of the formation of a polymer network was measured using known viscometry methods.
  • the crosslinking mixture was placed in a Teflon mold of 10 mm diameter and 15 mm height attached to the temperature controlled plate of a rheometer.
  • the addition of DMT to the crosslinking mixture defined time zero.
  • a cylindrical, stainless steel parallel plate geometry of 8 mm diameter was lowered until it was immersed approximately 1 mm into the polymer solution.
  • An oscillatory program consisting of a time sweep at an oscillatory frequency of 1 Hz and magnitude of 0.5% strain was used to monitor the viscosity as the composite cured.
  • the gel point was recorded as the time when the polymer viscosity suddenly increased.
  • the compressive strength at yield was defined by drawing a line parallel to the slope defining the modulus, beginning at 1.0% strain. The intersection of this line with the stress-strain curve was recorded as the compressive strength at yield.
  • PBS phosphate buffered saline
  • the equilibrium water content of PEG-DMA/PPF composites with ⁇ -TCP and PEG-DMA/PPF networks was determined by gravimetry with cylindrical specimens of 6 mm diameter and 12 mm height. The specimens were washed with 10 ml CH 2 Cl 2 to remove any unreacted components, air-dried for one day, and vacuum-dried for 6 h. The weight of the dried specimens was then recorded (W 1 ). Subsequently, specimens were immersed in PBS at room temperature. The weight of the specimens was monitored periodically and recorded when it reached an equilibrium value (W 2 ), which occurred after approximately after 24 h. The equilibrium water content was calculated as [(W 2 ⁇ W 1 )/W 2 ] ⁇ 100%.
  • the temperature increase during polymerization is an important consideration for injectable, in situ polymerizable formulations.
  • the maximum crosslinking temperature was not affected (p>0.05) by the double bond ratio of PEG-DMA/PPF or the ⁇ -TCP content, as shown in Table 2 below.
  • the maximum temperature increase for in vivo cross linking for the eight tested formulations was 1.5° C. and an average of 39.7° C. was calculated for the tested formulations. This relatively small temperature increase makes the present formulations very suitable for in situ polymerization and is much lower than the 94° C. reported for a conventional poly(methyl methacrylate) (PMMA) bone cement tested under similar conditions.
  • PMMA poly(methyl methacrylate)
  • the gel point data measured under an oscillatory program are also shown in Table 2.
  • the double bond ratio of PEG-DMA/PPF and the ⁇ -TCP content did not have an effect (p>0.05) on the gel point, which varied from 8.0 ⁇ 1.0 to 12.3 ⁇ 2.2 min, which is within the range of 5-15 minutes desirable for clinical use, and was not affected by the P-TCP content (p>0.05).
  • the decrease of gel point with increasing PEG-DMA/PPF double bond ratio was not significant (p>0.05).
  • An increase of the PEG-DMA/PPF double bond ratio should increase the number of active double bonds of methacrylate which may reduce the time frame for crosslinking but also decrease the relative concentration of fumarate double bonds.
  • the compressive strength at yield of specimens without ⁇ -TCP was in the range of 2.2 ⁇ 0.5 to 3.5 ⁇ 0.5 MPa.
  • PEG is a hydrophilic polyether and its incorporation into a PPF network forms a hydrogel with decreased mechanical properties.
  • the reinforcement of the mechanical properties of PEG-DMA/PPF crosslinked composites by ⁇ -TCP was not significant for specimens tested wet.
  • the present method for making PPF avoids the addition of a catalyst, which might otherwise be brought into the cross linked composite with PPF as an impurity. Moreover, the absence of a catalyst minimizes the reaction of the fumarate double bonds during PPF synthesis.
  • the proton NMR spectrum of PPF indicated that the integration ratio of the vinyl protons to the methyl protons was 2:3.4, which was close to the ratio of 2:3.33 calculated from the number average molecular weight, thus suggesting no loss of PPF unsaturation.

Abstract

New injectable, in situ crosslinkable biodegradable polymer composites comprise poly(propylene fumarate) (PPF), poly(ethylene glycol)-dimethacrylate (PEG-DMA), an, optionally, β-tricalcium phosphate (β-TCP). A method for controlling the crosslinking characteristics of the composites, including the maximum crosslinking temperature and the gel point, as well as the properties of the cross linked composites such as the compressive strength and modulus and the water holding capacity, is disclosed.

Description

    RELATED CASES
  • The present case claims the benefit of U.S. provisional applications Ser. No. 60/129577, filed Apr. 16, 1999, and entitled “Development of Biodegradable Bone Cement Based on Poly(Propylene Fumarate) and a Macromer,” Ser. No. 60/146,991, filed Aug. 3, 1999, and entitled “Synthesis of Poly(Propylene Fumarate) by Acylation of Propylene Glycol in the Presence of a Proton Scavenger,” Ser. No. 60/167,328, filed Nov. 24, 1999, and entitled “Preparation of an Injectable, in situ Polymerizable and Biodegradable Biomaterial Based On Poly(Propylene Fumarate) and Biodegradable Cross linking Reagents,” and Ser. No. 60/167,388, filed Nov. 24, 1999, and entitled “Injectable Biodegradable Polymer Composites Based on Poly(Propylene Fumarate) Cross linked with Poly(Ethylene Glycol)-Dimethacrylate and β-Tricalcium Phosphate,” all of which are incorporated herein by reference.[0001]
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • [0002] This work was funded by the National Institutes of Health R01-AR44381 and R01-DE13031.
  • TECHNICAL FIELD OF THE INVENTION
  • This invention relates to a compound for replacing or reconstructing rigid or semi-rigid living tissue. More particularly, the present invention relates to compositions comprising poly(propylene fumarate) cross linked with poly(ethylene glycol) and methods for making these compositions. [0003]
  • BACKGROUND OF THE INVENTION
  • In the field of tissue engineering, degradable biomaterials usually serve as a scaffold to provide mechanical support and a matrix for the ingrowth of new tissue. As new tissue forms on the scaffold, the biomaterial degrades until it is entirely dissolved. The degradation products are eliminated through the body's natural pathways, such as metabolic processes. [0004]
  • One example of the use of such biomaterials is as a temporary bone replacement. It is often desired to replace or reconstruct all or a portion of a living bone, such as when a bone has been broken or has been resected as a result of a bone tumor. In these instances, the missing bone can be replaced with a mechanical device, such as a pin, plate or the like, or it can be replaced with an implant that is designed to more closely resemble the original bone itself. Often these implants comprise biodegradable polymeric compounds or parts made from such compounds. It is contemplated that bone tissue will grow back into the pores of the implant and will gradually replace the entire implant as the implant itself is gradually degraded in the in vivo environment. For obvious reasons then, such implants should be biocompatible and non-toxic. [0005]
  • Poly(propylene fumarate) (PPF) is one such polymer. Poly(propylene fumarate) (hereinafter “PPF”) is an unsaturated linear polyester that degrades in the presence of water into propylene glycol and fumaric acid, degradation products that are easily cleared from the human body by normal metabolic processes. Because the fumarate double bonds in PPF are reactive and cross link at low temperatures, PPF has potential to be an effective in situ polymerizable biomaterial. The high mechanical strength of cured PPF matrices and their ability to be cross linked in situ makes them especially suitable for orthopedic application. Another advantage of cured PPF matrices is that they biodegrade into non-toxic propylene glycol and fumaric acid. On the basis of these unique properties, PPF has been formulated as bone cement, an orthopaedic scaffold for bone tissue regeneration, and a drug delivery system. [0006]
  • Several PPF-based formulation methods have been evaluated by varying such parameters as the molecular weight of PPF and the choice of cross linking reagents. For example, U.S. Pat. No. 5,733,951 discloses a composite mixture incorporating P(PF), a cross linking monomer (N-vinyl pyrrolidone), a porogen (sodium chloride), and a particulate phase (β-tricalcium phosphate) that can be injected or inserted into skeletal defects of irregular shape or size. [0007]
  • The properties of some PPF composites can be tailored for specific applications by varying different parameters, including crosslinking density and molecular weight of PPF. PPF composite formulations can include a porogen such as NaCl for initial porosity and a particulate ceramic such as β-TCP for mechanical reinforcement and increased osteoconductivity. PPF composite formulations can also include a vinyl monomer such as N-vinyl pyrrolidone, which serves as a crosslinking reagent. However, because this monomer is toxic, any unreacted amount during polymerization in situ may present a problem. [0008]
  • Poly(ethylene glycol), (PEG), is a hydrophilic polyether that has received much attention for use in biomaterials because low molecular weight PEG is passively excreted by the body. PEG has also been covalently bound to polyesters in an effort to increase polyester biocompatibility. The use of acrylated PEG as a nontoxic crosslinking reagent to produce polymer networks with acrylated poly(lactic acid) has been reported. To date however, PPF-based polymers cross-linked with PEG have not been made. Hence, it remains desirable to provide a poly(propylene fumarate) cross linked with poly(ethylene glycol) and a method for making it. The method for making would preferably include a method for controlling the mechanical properties of the resulting polymer. [0009]
  • SUMMARY OF THE INVENTION
  • The present invention comprises new, injectable biodegradable polymer composites based on PPF cross linked with biocompatible PEG-DMA and, if desired, β-TCP. The invention further provides the ability to control the crosslinking characteristics of the polymerizing composites and the mechanical properties of cross linked composites by varying the β-TCP content and the double bond ratio of PEG-DMA/PPF. The PPF/PEG-DMA networks produced according to the present invention have clinically acceptable gel times, cross-linking temperature increases of less than 2° C., and are suitable for use as injectable, biodegradable carriers for cell transplantation or drug delivery. [0010]
  • As used herein, the term “network” refers to polymeric molecules that have been cross linked so as to effectively form a continuous molecule. The term “gel” is sometimes used to refer to the same type of cross linked systems.[0011]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • For a better understanding of the present invention, reference will be made to the attached Figures, wherein: [0012]
  • FIG. 1 is a schematic chemical diagram illustrating a possible reaction scheme for crosslinking of PPF with PEG-DMA; [0013]
  • FIG. 2 is a plot illustrating the dependence of compressive strength at yield of PEG-DMA/PPF composites on the double bond ratio of PEG-DMA/PPF for composites incorporating β-TCP (33 wt %) and cross linked polymers without β-TCP, both dry and wet; [0014]
  • FIG. 3 is a plot illustrating the dependence of compressive modulus of PEG-DMA/PPF composites on the double bond ratio of PEG-DMA/PPF for composites incorporating β-TCP (33 wt %) and crosslinked polymers without β-TCP both tested dry and wet; and [0015]
  • FIG. 4 is a plot illustrating the water content of PEG-DMA/PPF composites incorporating β-TCP and cross linked polymers without β-TCP as a function of the double bond ratio of PEG-DMA/PPF after equilibrium in PBS.[0016]
  • DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT
  • The present invention includes novel PPF-based polymers and a method for making those polymers. The novel polymers comprise PPF cross linked with PEG, in which the fraction of PEG can be varied to control, among other things, the crosslinking characteristics of the composites, including the maximum crosslinking temperature and the gel point, and the properties of the cross linked composites, including its compressive strength and modulus and its water holding capacity. [0017]
  • Synthesis of PPF
  • PPF is preferably prepared by the method generally described in co-pending application Ser. No. PCT/US99/07912, filed Apr. 9, 1999, and entitled “Synthesis of Poly (Proplyene Fumarate) by Acylation of Propylene Glycol in the Presence of a Proton Scavenger,” which is incorporated herein by reference. Briefly, fumaryl chloride is added to a solution of propylene glycol in methylene chloride at 0° C. under nitrogen in the presence of K[0018] 2CO3. After addition of fumaryl chloride, the reaction mixture is stirred for an additional 2 hours at 0° C. and then water is added to dissolve the inorganic salt. The organic phase is separated and dried over Na2SO4. After filtration of the mixture and evaporation of the solvent, the resulting di(2-hydroxylpropyl) fumarate is converted to PPF by transesterification at 160° C. and 0.5 mm Hg.
  • The resulting polymer can be purified by solution precipitation, forming a viscous liquid. Gel permeation chromatography with a differential refractometer can be used to determine polymer molecular weight distributions. [0019]
  • Crosslinking of PPF
  • According to the present invention, PPF is crosslinked with PEG-DMA. FIG. 1 shows a possible reaction scheme for this reaction. In preferred reaction, PPF is mixed with PEG-DMA. An amount of BP is dissolved in CH[0020] 2Cl2 and the solution is added to the PEG-DMA/PPF mixture. If desired, β-TCP is added, followed by the addition of DMT under rapid stirring for 10 s. Once polymerization starts to take place, a cross linked polymeric network is formed in 10 to 15 min. The light brown polymeric network can be washed with acetone and then water to remove possible unreacted monomers.
  • Experimental Materials
  • Fumaryl chloride (Aldrich, Milwaukee, Wis.) was purified by distillation under nitrogen atmosphere. Propylene glycol, poly(ethylene-glycol)-dimethacrylate (PEG-DMA) (of number average molecular weight 875, liquid), benzoyl peroxide (BP), anhydrous potassium carbonate, Beta-tricalcium phosphate (β-TCP) particles (100 mesh), N,N-dimethyl-p-toluidine (DMT), and all solvents were purchased from commercial sources and used as received. [0021]
  • Experimental Design
  • Eight composite formulations were examined to assess the effects of PEG-DMA/PPF double bond ratio and β-TCP content on the maximum crosslinking temperature and gel point of the polymerizing composite pastes and also the compressive strength at yield, compressive modulus and equilibrium water content of the crosslinked composites. The different compositions of the composite formulations are set out in Table 1. The double bond ratio of PEG-DMA/PPF was used instead of the weight ratio because PEG-DMA is a macromer. It was calculated as follows: PEG-DMA/PPF double bond ratio=PEG-DMA/PPF weight ratio×(PPF number average molecular weight/PEG-DMA number average molecular weight)×(2/n), where n is the average number of fumarate double bonds in a PPF chain calculated as: n=(PPF number average molecular weight−76)/156. [0022]
    TABLE 1
    BP and DMT contents are 0.3 wt % and 0.15 wt %, respectively,
    for all formulations. (Percentage of BP, DMT and β-TCP based on
    total amount of PEG-DMA and PPF.)
    Weight ratio Double bond ratio β-TCP
    of PEG- of content
    Formulation DMA/PPF PEG-DMA/PPF (wt %)
    1 1 0.38 0
    2 2 0.75 0
    3 3 1.13 0
    4 5 1.88 0
    5 1 0.38 33
    6 2 0.75 33
    7 3 1.13 33
    8 5 1.88 33
  • Fumaryl chloride was added dropwise to a solution of propylene glycol in methylene chloride at 0° C. under nitrogen in the presence of K[0023] 2CO3. After addition of fumaryl chloride, the reaction mixture was stirred for an additional 2 h at 0° C. and then water was added to dissolve the inorganic salt. The organic phase was separated and dried over Na2SO4. After filtration of the mixture and evaporation of the solvent, the formed di(2-hydroxylpropyl) fumarate was converted to PPF by transesterification at 160° C. and 0.5 mm Hg. The produced polymer was purified by solution precipitation forming a viscous liquid.
  • Gel permeation chromatography with a differential refractometer (Waters 410, Milford, Mass.) was used to determine polymer molecular weight distributions. A Phenogel column (300×7.8 mm, 5 nm, mixed bed, Phenomenex, Torrance, Calif.) and a Phenogel guard column (50×7.8 mm, 5 nm, mixed bed, Phenomenex) were employed for a chloroform eluent flow rate of 1 ml/min. Polystyrene standards were utilized to obtain a calibration curve for calculating the polymer molecular weights. [0024]
  • In a typical reaction, 2 g PPF were mixed with 2 g PEG-DMA as a crosslinking reagent. 12 mg BP were dissolved in 0.1 ml CH[0025] 2Cl2 and the solution was added to the PEG-DMA/PPF mixture. β-TCP was added for those composites incorporating β-TCP, followed by the addition of 6 μl DMT under rapid stirring for 10 s.
  • Maximum Temperature
  • The temperature profile was recorded throughout the crosslinking process in a glass vial of 10 mm diameter and 24 mm length immersed into a 37° C. static water bath. The crosslinking mixture was placed in the glass vial and a thermocouple was inserted to half the depth of the vial. The temperature was measured every minute until it dropped to 37° C. and the maximum temperature was recorded. [0026]
  • Gel Point
  • The gel point corresponding to the onset of the formation of a polymer network was measured using known viscometry methods. The crosslinking mixture was placed in a Teflon mold of 10 mm diameter and 15 mm height attached to the temperature controlled plate of a rheometer. The addition of DMT to the crosslinking mixture defined time zero. A cylindrical, stainless steel parallel plate geometry of 8 mm diameter was lowered until it was immersed approximately 1 mm into the polymer solution. An oscillatory program consisting of a time sweep at an oscillatory frequency of 1 Hz and magnitude of 0.5% strain was used to monitor the viscosity as the composite cured. The gel point was recorded as the time when the polymer viscosity suddenly increased. [0027]
  • Mechanical Properties
  • The mechanical properties of PEG-DMA/PPF composites with β-TCP and PEG-DMA/PPF networks were determined under compression. For specimen preparation, the crosslinking mixture was placed into cylindrical vials of 6 mm diameter. After 6 h, the cross linked composites were removed from the vials and cut to 12 mm length cylinders using a diamond saw. The specimens were tested using an 858 Material Testing System mechanical testing machine, following the guidelines set in ASTM F451-95. Samples were compressed at a crosshead speed of 1 mm/min until failure with the load versus deformation curve recorded throughout. The compressive modulus was calculated as the slope of the initial linear portion of the stress-strain curve. The compressive strength at yield was defined by drawing a line parallel to the slope defining the modulus, beginning at 1.0% strain. The intersection of this line with the stress-strain curve was recorded as the compressive strength at yield. For the mechanical testing of wet specimens, the 12 mm length and 6 mm diameter cylinders were placed in phosphate buffered saline (PBS, pH 7.4) for 24 h. Specimens were swollen to approximately 14 mm length and 7 mm diameter, and were tested immediately upon removal from PBS as described above for dry specimens. [0028]
  • Equilibrium Water Content
  • The equilibrium water content of PEG-DMA/PPF composites with β-TCP and PEG-DMA/PPF networks was determined by gravimetry with cylindrical specimens of 6 mm diameter and 12 mm height. The specimens were washed with 10 ml CH[0029] 2Cl2 to remove any unreacted components, air-dried for one day, and vacuum-dried for 6 h. The weight of the dried specimens was then recorded (W1). Subsequently, specimens were immersed in PBS at room temperature. The weight of the specimens was monitored periodically and recorded when it reached an equilibrium value (W2), which occurred after approximately after 24 h. The equilibrium water content was calculated as [(W2−W1)/W2]×100%.
  • Statistical Analysis
  • All experiments were conducted in triplicate except, for the mechanical testing where n=5. The data were expressed as means±standard deviation. Single factor analysis of variance (ANOVA) was used to assess statistical significance of results. [0030]
  • Results
  • PPF with number average molecular weight of 1500 (corresponding to an average of 9.1 fumarate double bonds per macromolecular chain) and polydispersity index of 1.87 was obtained after 6 h transesterification. The proton NMR data were: [0031] 1H-NMR (250 MHz, CDCl3): δ 1.28 (m, CH3), 4.26 (m, CH2), 5.27 (m, CH), 6.84 (bs, CH=). The integration ratio of the vinyl protons to methyl protons was 2 to 3.4.
  • The temperature increase during polymerization is an important consideration for injectable, in situ polymerizable formulations. The maximum crosslinking temperature was not affected (p>0.05) by the double bond ratio of PEG-DMA/PPF or the β-TCP content, as shown in Table 2 below. The maximum temperature increase for in vivo cross linking for the eight tested formulations was 1.5° C. and an average of 39.7° C. was calculated for the tested formulations. This relatively small temperature increase makes the present formulations very suitable for in situ polymerization and is much lower than the 94° C. reported for a conventional poly(methyl methacrylate) (PMMA) bone cement tested under similar conditions. The present results also agree with those for injectable hydrogels of poly(propylene fumarate-co-ethylene glycol). The minimal temperature increase also makes the present formulations ideal for use as carriers for cells and/or bioactive molecules or drugs. This is because a excessive temperature increase can cause cell death or loss of drug bioactivity. [0032]
    TABLE 2
    Maximum crosslinking temperature and gel point for eight composite
    formulations. Data are presented as means ± standard deviation for
    n = 3.
    Maximum Temperature Gel point
    Formulation (° C.) (min)
    1 39.4 ± 0.8 12.6 ± 2.5
    2 39.8 ± 1.0 12.0 ± 2.0
    3 39.6 ± 0.8 10.3 ± 1.8
    4 40.0 ± 1.1  8.1 ± 0.6
    5 39.5 ± 0.6 12.3 ± 2.2
    6 39.9 ± 1.2 11.8 ± 2.0
    7 39.4 ± 0.9  9.7 ± 1.5
    8 40.0 ± 1.5  8.0 ± 1.0
  • The gel point data measured under an oscillatory program are also shown in Table 2. The double bond ratio of PEG-DMA/PPF and the β-TCP content did not have an effect (p>0.05) on the gel point, which varied from 8.0±1.0 to 12.3±2.2 min, which is within the range of 5-15 minutes desirable for clinical use, and was not affected by the P-TCP content (p>0.05). In addition, the decrease of gel point with increasing PEG-DMA/PPF double bond ratio was not significant (p>0.05). An increase of the PEG-DMA/PPF double bond ratio should increase the number of active double bonds of methacrylate which may reduce the time frame for crosslinking but also decrease the relative concentration of fumarate double bonds. [0033]
  • An increase in the PEG-DMA/PPF double bond ratio resulted in an increase in both compressive strength at yield and compressive modulus of the networks and cross linked composites, regardless of whether they were tested dry or wet (p<0.05), as shown in FIGS. 2 and 3. FIGS. 2 and 3 show, respectively, the dependence of the compressive strength at yield and the compressive modulus of PEG-DMA/PPF composites on the double bond ratio of PEG-DMA/PPF for composites incorporating β-TCP (33 wt %) (▪,▪) and crosslinked polymers without β-TCP (O,). Both were tested dry (O,□) and wet (,▪). Error bars represent means±standard deviation for n=5 [0034]
  • The incorporation of β-TCP caused a further enhancement of the mechanical properties (p<0.05). The compressive strength at yield of the networks tested dry ranged from 5.9±1.0 to 11.2±2.2 MPa, whereas that of the cross linked composites incorporating β-TCP ranged from 7.8±0.1 to 12.6±0.8 MPa. The compressive modulus was in the range of 30.2±13.5 to 58.4±6.2 MPa and 41.4±1.0 to 76.0±1.3 MPa for specimens without β-TCP and incorporating β-TCP, respectively. The compressive strength at yield and compressive modulus of the networks and composites with β-TCP tested wet were lower than the corresponding values of specimens tested dry. For example, in the wet state, the compressive strength at yield of specimens without β-TCP was in the range of 2.2±0.5 to 3.5±0.5 MPa. PEG is a hydrophilic polyether and its incorporation into a PPF network forms a hydrogel with decreased mechanical properties. The reinforcement of the mechanical properties of PEG-DMA/PPF crosslinked composites by β-TCP was not significant for specimens tested wet. [0035]
  • The equilibrium water content of PEG-DMA/PPF networks increased from 21.7±0.2 to 30.7±0.2% as the PEG-DMA/PPF double bond ratio increased from 0.38 to 1.88, as shown in FIG. 4. FIG. 4 shows the water content of PEG-DMA/PPF composites incorporating β-TCP (▪) and crosslinked polymers without β-TCP (O) as a function of the double bond ratio of PEG-DMA/PPF after equilibrium in PBS. Error bars represent means±standard deviation for n=3. Incorporation of β-TCP into the cross linked composites reduced their water content (p<0.05). [0036]
  • The present method for making PPF avoids the addition of a catalyst, which might otherwise be brought into the cross linked composite with PPF as an impurity. Moreover, the absence of a catalyst minimizes the reaction of the fumarate double bonds during PPF synthesis. The proton NMR spectrum of PPF indicated that the integration ratio of the vinyl protons to the methyl protons was 2:3.4, which was close to the ratio of 2:3.33 calculated from the number average molecular weight, thus suggesting no loss of PPF unsaturation. [0037]
  • The crosslinking density of PEG-DMA/PPF networks increased with the PEG-DMA/PPF double bond ratio resulting in increased mechanical properties of the PEG-DMA/PPF networks and crosslinked composites. The mechanical properties of the PEG-DMA/PPF networks did not suggest a PEG-DMA self-polymerization. This phenomenon can occur in PPF networks crosslinked with N-vinyl pyrrolidone due to formation of long cross links. No apparent volume changes were observed upon crosslinking. [0038]
  • Hence, it is possible to cross link PPF with PEG-DMA to form biodegradable hydrogels with tailored mechanical properties by varying the PEG-DMA/PPF double bond ratio. Although the mechanical properties of porous hydrogels may prove insufficient for replacement of human trabecular bone, the use of injectable, in situ crosslinkable hydrogels holds promise for the engineering of softer orthopaedic tissues such as cartilage. [0039]

Claims (13)

1. A polymer network comprising poly(propylene fumarate) and poly(ethylene glycol).
2. An injectable, in situ crosslinkable, biodegradable composite formulation comprising poly(propylene fumarate) and poly(ethylene glycol).
3. The composition according to claim 2, further including beta-tricalcium phosphate.
4. The composition according to claim 2 wherein the composition exhibits a temperature increase of less than 2° C. during cross linking.
5. The composition according to claim 2 wherein the composition exhibits a gel point between 5-15 minutes.
6. An injectable, in situ crosslinkable, biodegradable carrier for cell transplantation, comprising poly(propylene fumarate) and poly(ethylene glycol).
7. The composition according to claim 4, further including beta-tricalcium phosphate.
8. The composition according to claim 2 wherein the composition exhibits a temperature increase of less than 2° C. during cross linking.
9. The composition according to claim 2 wherein the composition exhibits a gel point between 5-15 minutes.
10. An injectable, in situ crosslinkable, biodegradable carrier for bioactive drug delivery, comprising poly(propylene fumarate) and poly(ethylene glycol).
11. The composition according to claim 5, further including beta-tricalcium phosphate.
12. The composition according to claim 2 wherein the composition exhibits a temperature increase of less than 2° C. during cross linking.
13. The composition according to claim 2 wherein the composition exhibits a gel point between 5-15 minutes.
US09/550,372 1999-04-16 2000-04-14 Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol) Expired - Fee Related US6384105B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/550,372 US6384105B1 (en) 1999-04-16 2000-04-14 Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12957799P 1999-04-16 1999-04-16
US14699199P 1999-08-03 1999-08-03
US16738899P 1999-11-24 1999-11-24
US16732899P 1999-11-24 1999-11-24
US09/550,372 US6384105B1 (en) 1999-04-16 2000-04-14 Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol)

Publications (2)

Publication Number Publication Date
US20020022676A1 true US20020022676A1 (en) 2002-02-21
US6384105B1 US6384105B1 (en) 2002-05-07

Family

ID=27494811

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/549,485 Expired - Fee Related US6423790B1 (en) 1999-04-16 2000-04-14 Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers
US09/550,372 Expired - Fee Related US6384105B1 (en) 1999-04-16 2000-04-14 Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol)
US09/549,483 Expired - Lifetime US6306821B1 (en) 1999-04-16 2000-04-14 Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol)
US10/127,117 Expired - Lifetime US6759485B2 (en) 1999-04-16 2002-04-22 Biodegradable poly (propylene fumarate) networks cross linked with poly (propylene fumarate) -diacrylate macromers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/549,485 Expired - Fee Related US6423790B1 (en) 1999-04-16 2000-04-14 Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers

Family Applications After (2)

Application Number Title Priority Date Filing Date
US09/549,483 Expired - Lifetime US6306821B1 (en) 1999-04-16 2000-04-14 Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol)
US10/127,117 Expired - Lifetime US6759485B2 (en) 1999-04-16 2002-04-22 Biodegradable poly (propylene fumarate) networks cross linked with poly (propylene fumarate) -diacrylate macromers

Country Status (9)

Country Link
US (4) US6423790B1 (en)
EP (3) EP1194463B1 (en)
JP (3) JP2002542349A (en)
KR (3) KR100619611B1 (en)
AT (3) ATE357468T1 (en)
AU (3) AU770579B2 (en)
CA (3) CA2369758C (en)
DE (3) DE60034045T2 (en)
WO (3) WO2000063263A1 (en)

Cited By (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040193255A1 (en) * 2003-03-28 2004-09-30 Shanley John F. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20050032209A1 (en) * 2003-06-27 2005-02-10 Messina Darin J. Regeneration and repair of neural tissue using postpartum-derived cells
WO2005099667A2 (en) * 2004-04-07 2005-10-27 Bausch & Lomb Incorporated Drug delivery compositions
WO2006032075A1 (en) 2004-09-24 2006-03-30 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US20060166361A1 (en) * 2004-12-21 2006-07-27 Agnieszka Seyda Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
US20070141700A1 (en) * 2005-12-19 2007-06-21 Ethicon, Incorporated In vitro expansion of postpartum-derived cells in roller bottles
US20070160588A1 (en) * 2005-12-28 2007-07-12 Ethicon, Incorporated Treatment Of Peripheral Vascular Disease Using Postpartum-Derived Cells
US20070264269A1 (en) * 2005-12-16 2007-11-15 Ethicon, Incorporated Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US20080145934A1 (en) * 2004-09-28 2008-06-19 Ian Ross Harris Tissue-engineering scaffolds containing self-assembled-peptide hydrogels
US20090074728A1 (en) * 2005-04-12 2009-03-19 Stan Gronthos Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
US20090092653A1 (en) * 2007-10-05 2009-04-09 Ethicon, Incorporated Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US20090166178A1 (en) * 2007-12-20 2009-07-02 Ethicon, Incorporated Methods for sterilizing materials containing biologically active agents
US20090286907A1 (en) * 2008-01-23 2009-11-19 Beltz Mark W Fumaric Acid/Diol Polyesters and Their Manufacture and Use
US20100159588A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Conditioned media and methods of making a conditioned media
US20100159025A1 (en) * 2003-06-27 2010-06-24 Ethicon, Incorporated Systemically and locally administered cells for neuropathic pain
US20100158880A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Regeneration and repair of neural tissue following injury
WO2010071864A1 (en) 2008-12-19 2010-06-24 Ethicon, Incorporated Treatment of lung and pulmonary diseases and disorders
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
US20100215714A1 (en) * 2003-06-27 2010-08-26 Ethicon, Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum-derived cells
US20100247499A1 (en) * 2009-03-26 2010-09-30 Ethicon, Inc. hUTC AS THERAPY FOR ALZHEIMER'S DISEASE
WO2010111631A1 (en) 2009-03-25 2010-09-30 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
US20100272803A1 (en) * 2003-06-27 2010-10-28 Sanjay Mistry Repair and regeneration of ocular tissue using postpartum-derived cells
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
WO2011041478A1 (en) 2009-10-02 2011-04-07 Baxter International Inc. Hematopoietic stem cells for use in the treatment of a kidney injury
EP2348105A1 (en) 2004-09-24 2011-07-27 Angioblast Systems Incorporated Multipotential expanded mesenchymal precursor cell progeny (MEMP) and uses thereof
WO2011094181A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
US20110223205A1 (en) * 2003-06-27 2011-09-15 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
EP2368973A1 (en) 2005-10-13 2011-09-28 Anthrogenesis Corporation Production Of Oligodendrocytes From Placenta-Derived Stem Cells
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
EP2418271A2 (en) 2006-10-23 2012-02-15 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2471906A2 (en) 2005-12-29 2012-07-04 Anthrogenesis Corporation Placental stem cell populations
WO2012092458A2 (en) 2010-12-30 2012-07-05 Anthrogenesis Corporation Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
WO2012092480A1 (en) 2010-12-30 2012-07-05 Anthirogenesis Corporation Compositions comprising amnion derived adherent cells and platelet-rich plasma
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
EP2530145A1 (en) 2005-10-13 2012-12-05 Anthrogenesis Corporation Immunomodulation using placental stem cells
WO2013022447A1 (en) 2011-08-10 2013-02-14 Advanced Technologies And Regenerative Medicine, Llc Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
EP2630959A1 (en) 2007-02-12 2013-08-28 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
WO2013126590A2 (en) 2012-02-21 2013-08-29 Baxter International Inc. Pharmaceutical composition comprising cd34+ cells
EP2633861A1 (en) 2008-08-22 2013-09-04 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2013163230A2 (en) * 2012-04-24 2013-10-31 Midori Renewables, Inc. Bio-based polymers and methods of producing thereof
WO2013173376A1 (en) 2012-05-14 2013-11-21 DePuy Synthes Products, LLC. hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS
WO2014011881A2 (en) 2012-07-11 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014063035A2 (en) 2012-10-19 2014-04-24 Anthrogenesis Corporation Treatment of pain using amnion derived adherent cells
US8815587B2 (en) 2003-06-27 2014-08-26 DePuy Synthes Products, LLC Postpartum cells derived from umbilical tissue and methods of making and using the same
EP2783692A1 (en) 2007-09-28 2014-10-01 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US9040035B2 (en) 2011-06-01 2015-05-26 Anthrogenesis Corporation Treatment of pain using placental stem cells
US9079171B2 (en) 2011-02-28 2015-07-14 Midori Usa, Inc. Polymeric acid catalysts and uses thereof
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9238845B2 (en) 2012-08-24 2016-01-19 Midori Usa, Inc. Methods of producing sugars from biomass feedstocks
WO2016109668A1 (en) 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
US9464118B2 (en) 2012-04-05 2016-10-11 Forschungszentrum Juelich Gmbh Polymers containing multivalent amyloid-beta-binding D-peptides and their use
EP3088512A1 (en) 2010-04-07 2016-11-02 Anthrogenesis Corporation Use of placental stem cells for treating heart and circulatory diseases by promoting angiogenesis
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9591845B2 (en) 2012-04-05 2017-03-14 Forschungszentrum Juelich Gmbh Method for treating blood, blood products and organs
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9611513B2 (en) 2011-12-23 2017-04-04 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue derived cells
WO2018009385A1 (en) 2016-07-05 2018-01-11 Janssen Biotech, Inc. Treatment of retinal vascular disease using progenitor cells
WO2018106742A1 (en) 2016-12-05 2018-06-14 Celularity, Inc. Treatment of lymphedema and related conditions using placental adherent cells
EP3424514A1 (en) 2007-08-06 2019-01-09 Mesoblast, Inc. Method for generating, repairing and/or maintaining connective tissue in vivo
WO2019068048A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. Placenta-derived intermediate natural killer (pink) cells for treatment of glioblastoma
US10293079B2 (en) 2014-05-05 2019-05-21 Sealantis Ltd. Biological adhesives and sealants and methods of using the same
EP3556215A1 (en) 2012-12-14 2019-10-23 Celularity, Inc. Anoikis resistant placental stem cells and uses thereof
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
CN112175191A (en) * 2020-09-22 2021-01-05 中山大学 Novel crosslinkable degradable multi-block copolymer and preparation method and application thereof
US10967005B2 (en) 2013-03-15 2021-04-06 Celgene Corporation Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
EP3882336A1 (en) 2013-03-14 2021-09-22 Celularity Inc. Enhanced placental stem cells and uses thereof
US11130820B2 (en) 2012-12-20 2021-09-28 Celgene Corporation Chimeric antigen receptors
GB2594243A (en) * 2020-04-15 2021-10-27 Arterius Ltd A bone cement
EP3957315A1 (en) 2015-09-15 2022-02-23 Celularity Inc. Treatment of diabetic peripheral neuropathy using placental cells
CN114249863A (en) * 2022-01-20 2022-03-29 西安交通大学 Hydrogen bond enhanced photocuring hard tissue adhesive and preparation method and use method thereof
WO2022236187A1 (en) 2021-05-07 2022-11-10 Children's Hospital Los Angeles Methods for making stem cell-derived enteric neural crest cells and their use in enteric neuropathy treatment

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369758C (en) 1999-04-16 2007-04-03 Wm. Marsh Rice University Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol)
US6884778B2 (en) * 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
EP1405871A4 (en) * 2001-05-30 2004-11-17 Mitsubishi Kagaku Iatron Inc Method of bonding substance to be incorporated to polymer terminal
JP2004536909A (en) * 2001-06-28 2004-12-09 ダブリューエム・マーシュ・ライス・ユニバーシティー Photocrosslinking of diethyl fumarate / poly (propylene fumarate) biomaterial
US20050064587A1 (en) * 2001-09-07 2005-03-24 Lawrence Rosenberg Pancreatic small cells and uses thereof
US7629388B2 (en) * 2001-11-20 2009-12-08 William Marsh Rice University Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion
DE10206517A1 (en) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depot medicinal products, carrier materials for depot medicinal products and processes for their production
US6884432B2 (en) * 2002-04-25 2005-04-26 Mayo Foundation For Medical Education And Research Blend, cross-linkable poly(propylene fumarate) for immobilization and controlled drug delivery
EP1741457A1 (en) * 2002-08-09 2007-01-10 Ottawa Health Research Institute Ocular implant
CA2498717A1 (en) * 2002-09-13 2004-03-25 Ocular Sciences, Inc. Devices and methods for improving vision
WO2004044012A1 (en) 2002-11-12 2004-05-27 The Polymer Technology Group Incorporated Control of polymer surface molecular architecture via amphipathic endgroups
US7186789B2 (en) * 2003-06-11 2007-03-06 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings
ATE464341T1 (en) * 2003-07-01 2010-04-15 Mayo Foundation HYDROXYAPATITE GRAFTED FUMARATE-BASED MACROMONOMERS FOR BIODEGRADABLE COMPOSITES
AU2004255225A1 (en) * 2003-07-01 2005-01-20 Mayo Foundation For Medical Education And Research Self-crosslinkable poly(caprolactone fumarate)
AU2005211362B2 (en) 2004-02-02 2008-03-13 Ambrx, Inc. Modified human interferon polypeptides and their uses
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
CA2587308A1 (en) 2004-11-12 2006-05-18 Mayo Foundation For Medical Education And Research Photocrosslinkable poly(caprolactone fumarate)
JP2008525473A (en) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Modified human growth hormone
WO2006071840A2 (en) 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP4990792B2 (en) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド Compositions of aminoacyl-tRNA synthetases and uses thereof
MX2007007591A (en) 2004-12-22 2007-07-25 Ambrx Inc Methods for expression and purification of recombinant human growth hormone.
ATE511439T1 (en) * 2005-04-29 2011-06-15 Mayo Foundation HYDROPHILIC/HYDROPHOBIC POLYMER NETWORK BASED ON POLY(CAPROLACTONE FUMARATE), POLY(ETHYLENE GLYCOLFUMARATE) AND COPOLYMERS THEREOF
JP2008541769A (en) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド Improved human interferon molecules and their use
PT2339014E (en) 2005-11-16 2015-10-13 Ambrx Inc Methods and compositions comprising non-natural amino acids
TW200740416A (en) * 2006-02-08 2007-11-01 Coopervision Inc Corneal onlays and related methods
US7883520B2 (en) * 2006-04-10 2011-02-08 Forsight Labs, Llc Corneal epithelial pocket formation systems, components and methods
US8114150B2 (en) * 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
JP5451390B2 (en) 2006-09-08 2014-03-26 アンブルックス,インコーポレイテッド Transcription of suppressor TRNA in vertebrate cells
MX2009002523A (en) 2006-09-08 2009-03-20 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their uses.
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
WO2008121563A2 (en) 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
CN102224238B (en) 2008-09-26 2015-06-10 Ambrx公司 Non-natural amino acid replication-dependent microorganisms and vaccines
CN102232085A (en) 2008-09-26 2011-11-02 Ambrx公司 Modified animal erythropoietin polypeptides and their uses
US20100087920A1 (en) * 2008-10-07 2010-04-08 Forsight Labs, Llc Corneal Onlay Lenses and Related Methods for Improving Vision of Presbyopic Patients
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN107056929A (en) 2009-12-21 2017-08-18 Ambrx 公司 Porcine somatotropin polypeptide and its purposes by modification
US9144598B2 (en) 2010-03-05 2015-09-29 University of Pittsburgh—of the Commonwealth System of Higher Education Reverse thermal gels and their use in cell therapy
US9132199B2 (en) 2010-03-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Reverse thermal gels and uses therefor
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SG187736A1 (en) 2010-08-17 2013-03-28 Ambrx Inc Modified relaxin polypeptides and their uses
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
BR112013028570A2 (en) * 2011-05-09 2019-09-24 Institut Quim De Sarria polymeric nanoparticles for drug delivery
DE102012102999A1 (en) * 2012-04-05 2013-10-10 Forschungszentrum Jülich GmbH Treating blood, blood products and/or organs under in vitro, and ex vivo condition, involves obtaining blood, blood products and/or organs from human or animal body and removing amyloid beta oligomers from products
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP3584255B1 (en) 2012-08-31 2022-02-16 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
ES2865473T3 (en) 2013-07-10 2021-10-15 Sutro Biopharma Inc Antibodies Comprising Multiple Site-Specific Unnatural Amino Acid Residues, Methods for Their Preparation, and Methods of Use
US10173357B2 (en) 2013-09-26 2019-01-08 Northwestern University Poly(ethylene glycol) cross-linking of soft materials to tailor viscoelastic properties for bioprinting
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
TW202124419A (en) 2014-10-24 2021-07-01 美商必治妥美雅史谷比公司 Modified fgf-21 polypeptides and uses thereof
GB201603296D0 (en) 2016-02-25 2016-04-13 Ucl Business Plc Chemotactic,drug-containing polymersomes
GB201604553D0 (en) * 2016-03-17 2016-05-04 Ucl Business Plc Fumarate polymersomes
CN106693039B (en) * 2017-01-24 2019-10-01 南开大学 A kind of preparation method of the medical aquogel with good biological adhesiveness
AU2018214596A1 (en) 2017-02-02 2019-08-08 The University Of Akron Functionalized poly(propylene fumarate) polymers made by ring opening polymerization using magnesium catalysts
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CA3072503A1 (en) * 2017-08-07 2019-02-14 The University Of Akron Synthesis and characterization of well defined poly(propylene fumarate) and poly(ethylene glycol) block copolymers
CN116948006A (en) 2018-09-11 2023-10-27 北京泰德制药股份有限公司 Interleukin-2polypeptide conjugate and use thereof
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
US11384176B2 (en) 2020-06-26 2022-07-12 Saudi Arabian Oil Company Method of producing acryloyl monomers and acryloyl-based polymers
CA3190606A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CN112973277B (en) * 2021-03-17 2022-06-14 济南大学 Preparation and application of hyperbranched high-molecular polymer filter pad
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701748A (en) * 1966-07-20 1972-10-31 Rohm & Haas Unsaturated polyester resinous compositions
DE2061421A1 (en) * 1970-12-14 1972-06-29 Rohm & Haas Liquid polyester compsn comprising polyester thermoplastic polymer - and monomer characterised by very low shrinkage during curing
US4331735A (en) * 1980-06-26 1982-05-25 The General Tire & Rubber Company One component in-mold coating
US5286763A (en) * 1983-03-22 1994-02-15 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
US4722948A (en) * 1984-03-16 1988-02-02 Dynatech Corporation Bone replacement and repair putty material from unsaturated polyester resin and vinyl pyrrolidone
US5989579A (en) * 1986-10-02 1999-11-23 Escalon Medical Corp. Ocular insert with anchoring protrusions
US4843112A (en) 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
JPH072836B2 (en) * 1987-08-18 1995-01-18 帝人株式会社 Water dispersible polyester
US4888413A (en) * 1988-01-11 1989-12-19 Domb Abraham J Poly(propylene glycol fumarate) compositions for biomedical applications
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
CA2056384C (en) * 1989-06-05 1998-06-23 Tobin N. Gerhart Bioerodible polymers for drug delivery in bone
FI904598A0 (en) * 1989-10-10 1990-09-18 Wrigley W M Jun Co GRADVIS AEMNESFRIGOERANDE STRUKTURER SOM FRAMSTAELLTS MED FIBERSPINNINGSTEKNIK.
FR2661682B1 (en) * 1990-05-04 1993-12-10 Norsolor NEW RESINOUS COMPOSITIONS BASED ON UNSATURATED POLYESTER RESINS AND NEW ANTI-SHRINKAGE ADDITIVES.
CA2101742C (en) * 1991-02-01 2005-04-12 Abraham J. Domb Biodegradable polymer blends for drug delivery
DK0627911T3 (en) * 1992-02-28 2000-11-20 Univ Texas Photopolymerizable biodegradable hydrogels as tissue contact materials and controlled release carriers
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
ATE151084T1 (en) * 1992-07-24 1997-04-15 Rohm & Haas POLYESTER WITH METHACRYLATE GROUPS
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5522895A (en) 1993-07-23 1996-06-04 Rice University Biodegradable bone templates
US5733951A (en) * 1994-04-28 1998-03-31 Yaszemski; Michael J. Poly(propylene fumarate)
US5527864A (en) * 1995-08-08 1996-06-18 Suggs; Laura J. Poly(propylene fumarate-co-ethylene oxide)
PT1704878E (en) 1995-12-18 2013-07-17 Angiodevice Internat Gmbh Crosslinked polymer compositions and methods for their use
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US5945457A (en) * 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
DE69924369D1 (en) 1998-04-10 2005-04-28 Univ Rice William M SYNTHESIS OF POLY (PROPYLENE FUMARATE) BY ACETYLATION OF PROPYLENE GLYCOL IN THE PRESENCE OF A PROTONATE FENDER
CA2369758C (en) 1999-04-16 2007-04-03 Wm. Marsh Rice University Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol)

Cited By (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040193255A1 (en) * 2003-03-28 2004-09-30 Shanley John F. Therapeutic agent delivery device with controlled therapeutic agent release rates
EP2338980A2 (en) 2003-06-27 2011-06-29 Ethicon, Inc. Regeneration and repair of neural tissue using postpartum umbilical cord -derived cells
US20050058631A1 (en) * 2003-06-27 2005-03-17 Kihm Anthony J. Postpartum cells derived from placental tissue, and methods of making and using the same
US20050054098A1 (en) * 2003-06-27 2005-03-10 Sanjay Mistry Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US10383898B2 (en) 2003-06-27 2019-08-20 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US20050058630A1 (en) * 2003-06-27 2005-03-17 Harris Ian Ross Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US10220059B2 (en) 2003-06-27 2019-03-05 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US8318483B2 (en) 2003-06-27 2012-11-27 Advanced Technologies And Regenerative Medicine, Llc Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US8361459B2 (en) 2003-06-27 2013-01-29 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders using postpartum-derived cells
US20050032209A1 (en) * 2003-06-27 2005-02-10 Messina Darin J. Regeneration and repair of neural tissue using postpartum-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US20060154367A1 (en) * 2003-06-27 2006-07-13 Ethicon, Incorporated Cartilage and bone repair and regeneration using postpartum-derived cells
US20060153817A1 (en) * 2003-06-27 2006-07-13 Ethicon, Incorporated Cartilage and bone repair and regeneration using postpartum-derived cells
US20060154366A1 (en) * 2003-06-27 2006-07-13 Laura Brown Treatment of osteochondral diseases using postpartum-derived cells and products thereof
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US20060153816A1 (en) * 2003-06-27 2006-07-13 Laura Brown Soft tissue repair and regeneration using postpartum-derived cells and cell products
US20060153818A1 (en) * 2003-06-27 2006-07-13 Ethicon, Incorporated Cartilage and bone repair and regeneration using postpartum-derived cells
US8658152B2 (en) 2003-06-27 2014-02-25 DePuy Synthes Products, LLC Regeneration and repair of neural tissue using postpartum-derived cells
EP2399990A1 (en) 2003-06-27 2011-12-28 Ethicon, Inc Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
US20060188983A1 (en) * 2003-06-27 2006-08-24 Ethicon Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US20060234376A1 (en) * 2003-06-27 2006-10-19 Ethicon Incorporated Repair and regeneration of ocular tissue using postpartum-derived cells
US20070009494A1 (en) * 2003-06-27 2007-01-11 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US20070014771A1 (en) * 2003-06-27 2007-01-18 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US20070036767A1 (en) * 2003-06-27 2007-02-15 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US11191789B2 (en) 2003-06-27 2021-12-07 DePuy Synthes Products, Inc. Cartilage and bone repair and regeneration using postpartum-derived cells
US11179422B2 (en) 2003-06-27 2021-11-23 DePuy Synthes Products, Inc. Method of differentiating umbilical cord tissue into a chondrogenic phenotype
US11000554B2 (en) 2003-06-27 2021-05-11 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US8703121B2 (en) 2003-06-27 2014-04-22 DePuy Synthes Products, LLC Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US7413734B2 (en) 2003-06-27 2008-08-19 Ethicon, Incorporated Treatment of retinitis pigmentosa with human umbilical cord cells
US10758576B2 (en) 2003-06-27 2020-09-01 DePuy Synthes Products, Inc. Soft tissue repair and regeneration using postpartum-derived cells and cell products
US7510873B2 (en) 2003-06-27 2009-03-31 Ethicon, Incorporated Postpartum cells isolated from umbilical cord tissue, and methods of making and using the same
US10744164B2 (en) 2003-06-27 2020-08-18 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US7524489B2 (en) 2003-06-27 2009-04-28 Ethicon Incorporated Regeneration and repair of neural tissue using postpartum-derived cells
US10500234B2 (en) 2003-06-27 2019-12-10 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US7560276B2 (en) 2003-06-27 2009-07-14 Ethicon, Incorporated Soft tissue repair and regeneration using postpartum-derived cells
US20050058629A1 (en) * 2003-06-27 2005-03-17 Harmon Alexander M. Soft tissue repair and regeneration using postpartum-derived cells
US20100159025A1 (en) * 2003-06-27 2010-06-24 Ethicon, Incorporated Systemically and locally administered cells for neuropathic pain
US20050037491A1 (en) * 2003-06-27 2005-02-17 Sanjay Mistry Repair and regeneration of ocular tissue using postpartum-derived cells
US10195233B2 (en) 2003-06-27 2019-02-05 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US10039793B2 (en) 2003-06-27 2018-08-07 DePuy Synthes Products, Inc. Soft tissue repair and regeneration using postpartum-derived cells and cell products
US9717763B2 (en) 2003-06-27 2017-08-01 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US20100210013A1 (en) * 2003-06-27 2010-08-19 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US20100215714A1 (en) * 2003-06-27 2010-08-26 Ethicon, Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum-derived cells
US9579351B2 (en) 2003-06-27 2017-02-28 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US20100272803A1 (en) * 2003-06-27 2010-10-28 Sanjay Mistry Repair and regeneration of ocular tissue using postpartum-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9504719B2 (en) 2003-06-27 2016-11-29 DePuy Synthes Products, Inc. Soft tissue repair and regeneration using postpartum-derived cells and cell products
US9498501B2 (en) 2003-06-27 2016-11-22 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
EP2322599A2 (en) 2003-06-27 2011-05-18 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue and methods of making and using the same for repair and regeneration of soft tissue
EP2336298A2 (en) 2003-06-27 2011-06-22 Ethicon, Incorporated Postpartum cells derived from placental tissue and methods of making and using the same
EP2338981A2 (en) 2003-06-27 2011-06-29 Ethicon, Incorporated Repair and regeneration of ocular tissue using postpartum umbilical cord-derived cells
US8277796B2 (en) 2003-06-27 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc Regeneration and repair of neural tissue using postpartum-derived cells
EP2341131A2 (en) 2003-06-27 2011-07-06 Ethicon, Incorporated Repair and regeneration of cartilage and bone using postpartum-derived cells
US8815587B2 (en) 2003-06-27 2014-08-26 DePuy Synthes Products, LLC Postpartum cells derived from umbilical tissue and methods of making and using the same
US9234172B2 (en) 2003-06-27 2016-01-12 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US20110223205A1 (en) * 2003-06-27 2011-09-15 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
WO2005099667A2 (en) * 2004-04-07 2005-10-27 Bausch & Lomb Incorporated Drug delivery compositions
WO2005099667A3 (en) * 2004-04-07 2006-06-01 Bausch & Lomb Drug delivery compositions
US20060018949A1 (en) * 2004-04-07 2006-01-26 Bausch & Lomb Incorporated Injectable biodegradable drug delivery system
WO2006032075A1 (en) 2004-09-24 2006-03-30 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
EP2360242A1 (en) 2004-09-24 2011-08-24 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal procursor cells (MPC)
EP2348105A1 (en) 2004-09-24 2011-07-27 Angioblast Systems Incorporated Multipotential expanded mesenchymal precursor cell progeny (MEMP) and uses thereof
EP2361970A1 (en) 2004-09-24 2011-08-31 Angioblast Systems Incorporated Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
US20080145934A1 (en) * 2004-09-28 2008-06-19 Ian Ross Harris Tissue-engineering scaffolds containing self-assembled-peptide hydrogels
US8039258B2 (en) 2004-09-28 2011-10-18 Ethicon, Inc. Tissue-engineering scaffolds containing self-assembled-peptide hydrogels
US20060166361A1 (en) * 2004-12-21 2006-07-27 Agnieszka Seyda Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
US8367405B2 (en) 2005-04-12 2013-02-05 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
US9783617B2 (en) 2005-04-12 2017-10-10 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
US20090074728A1 (en) * 2005-04-12 2009-03-19 Stan Gronthos Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
EP2399991A1 (en) 2005-04-12 2011-12-28 Angioblast Systems Incorporated Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
EP3327116A1 (en) 2005-04-12 2018-05-30 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
EP2530145A1 (en) 2005-10-13 2012-12-05 Anthrogenesis Corporation Immunomodulation using placental stem cells
EP3031909A1 (en) 2005-10-13 2016-06-15 Anthrogenesis Corporation Immunomodulation using placental stem cells
EP2368973A1 (en) 2005-10-13 2011-09-28 Anthrogenesis Corporation Production Of Oligodendrocytes From Placenta-Derived Stem Cells
EP2530146A1 (en) 2005-10-13 2012-12-05 Anthrogenesis Corporation Immunomodulation using placental stem cells
US20070264269A1 (en) * 2005-12-16 2007-11-15 Ethicon, Incorporated Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9175261B2 (en) 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US8741638B2 (en) 2005-12-19 2014-06-03 DePuy Synthes Products, LLC In vitro expansion of postpartum-derived cells in roller bottles
US20070141700A1 (en) * 2005-12-19 2007-06-21 Ethicon, Incorporated In vitro expansion of postpartum-derived cells in roller bottles
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US20070160588A1 (en) * 2005-12-28 2007-07-12 Ethicon, Incorporated Treatment Of Peripheral Vascular Disease Using Postpartum-Derived Cells
US9585918B2 (en) 2005-12-28 2017-03-07 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
EP2471904A2 (en) 2005-12-29 2012-07-04 Anthrogenesis Corporation Placental stem cell populations
EP3486314A2 (en) 2005-12-29 2019-05-22 Celularity, Inc. Placental stem cell populations
EP2471907A2 (en) 2005-12-29 2012-07-04 Anthrogenesis Corporation Placental stem cell populations
EP2471903A2 (en) 2005-12-29 2012-07-04 Anthrogenesis Corporation Placental stem cell populations
EP2471905A2 (en) 2005-12-29 2012-07-04 Anthrogenesis Corporation Placental stem cell populations
EP2471906A2 (en) 2005-12-29 2012-07-04 Anthrogenesis Corporation Placental stem cell populations
EP2420568A2 (en) 2006-10-23 2012-02-22 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2420567A2 (en) 2006-10-23 2012-02-22 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP3483263A1 (en) 2006-10-23 2019-05-15 Celularity, Inc. Methods and compositions for treatment of bone defects with placental cell populations
EP2418271A2 (en) 2006-10-23 2012-02-15 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP3103462A1 (en) 2007-02-12 2016-12-14 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
EP3763376A1 (en) 2007-02-12 2021-01-13 Celularity, Inc. Treatment of inflammatory diseases using placental stem cells
EP2915537A2 (en) 2007-02-12 2015-09-09 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
EP2630959A1 (en) 2007-02-12 2013-08-28 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
EP3424514A1 (en) 2007-08-06 2019-01-09 Mesoblast, Inc. Method for generating, repairing and/or maintaining connective tissue in vivo
EP2783692A1 (en) 2007-09-28 2014-10-01 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP3524253A1 (en) 2007-09-28 2019-08-14 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US8034329B2 (en) 2007-10-05 2011-10-11 Advanced Technologies And Regenerative Medicine, Llc Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US20090092653A1 (en) * 2007-10-05 2009-04-09 Ethicon, Incorporated Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US20090166178A1 (en) * 2007-12-20 2009-07-02 Ethicon, Incorporated Methods for sterilizing materials containing biologically active agents
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
US8574897B2 (en) 2007-12-20 2013-11-05 DePuy Synthes Products, LLC Methods for sterilizing materials containing biologically active agents
US20090286907A1 (en) * 2008-01-23 2009-11-19 Beltz Mark W Fumaric Acid/Diol Polyesters and Their Manufacture and Use
EP2633861A1 (en) 2008-08-22 2013-09-04 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2010071864A1 (en) 2008-12-19 2010-06-24 Ethicon, Incorporated Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
US20100158880A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Regeneration and repair of neural tissue following injury
WO2010071862A1 (en) 2008-12-19 2010-06-24 Ethicon, Incorporated Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
US20100159588A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Conditioned media and methods of making a conditioned media
US10557116B2 (en) 2008-12-19 2020-02-11 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
WO2010111631A1 (en) 2009-03-25 2010-09-30 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
EP3489352A1 (en) 2009-03-25 2019-05-29 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
US20100247499A1 (en) * 2009-03-26 2010-09-30 Ethicon, Inc. hUTC AS THERAPY FOR ALZHEIMER'S DISEASE
US8722034B2 (en) 2009-03-26 2014-05-13 Depuy Synthes Products Llc hUTC as therapy for Alzheimer's disease
US9943552B2 (en) 2009-03-26 2018-04-17 DePuy Synthes Products, Inc. hUTC as therapy for Alzheimer's disease
US20110091427A1 (en) * 2009-10-02 2011-04-21 Baxter International Inc. Methods for treating a kidney injury
WO2011041478A1 (en) 2009-10-02 2011-04-07 Baxter International Inc. Hematopoietic stem cells for use in the treatment of a kidney injury
EP3284818A1 (en) 2010-01-26 2018-02-21 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
WO2011094181A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
EP3088512A1 (en) 2010-04-07 2016-11-02 Anthrogenesis Corporation Use of placental stem cells for treating heart and circulatory diseases by promoting angiogenesis
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2012092480A1 (en) 2010-12-30 2012-07-05 Anthirogenesis Corporation Compositions comprising amnion derived adherent cells and platelet-rich plasma
WO2012092458A2 (en) 2010-12-30 2012-07-05 Anthrogenesis Corporation Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
WO2012112576A1 (en) 2011-02-14 2012-08-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9205418B2 (en) 2011-02-28 2015-12-08 Midori Usa, Inc. Polymeric acid catalysts and uses thereof
US9079171B2 (en) 2011-02-28 2015-07-14 Midori Usa, Inc. Polymeric acid catalysts and uses thereof
US10787527B2 (en) 2011-02-28 2020-09-29 Cadena Bio, Inc. Polymeric acid catalysts and uses thereof
US10131721B2 (en) 2011-02-28 2018-11-20 Cadena Bio, Inc. Polymeric acid catalysts and uses thereof
US11090339B2 (en) 2011-06-01 2021-08-17 Celularity Inc. Treatment of pain using placental stem cells
US9040035B2 (en) 2011-06-01 2015-05-26 Anthrogenesis Corporation Treatment of pain using placental stem cells
EP3443968A1 (en) 2011-06-01 2019-02-20 Celularity, Inc. Treatment of pain using placental stem cells
WO2013022447A1 (en) 2011-08-10 2013-02-14 Advanced Technologies And Regenerative Medicine, Llc Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9611513B2 (en) 2011-12-23 2017-04-04 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue derived cells
US10724105B2 (en) 2011-12-23 2020-07-28 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
WO2013126590A2 (en) 2012-02-21 2013-08-29 Baxter International Inc. Pharmaceutical composition comprising cd34+ cells
US9591845B2 (en) 2012-04-05 2017-03-14 Forschungszentrum Juelich Gmbh Method for treating blood, blood products and organs
US9464118B2 (en) 2012-04-05 2016-10-11 Forschungszentrum Juelich Gmbh Polymers containing multivalent amyloid-beta-binding D-peptides and their use
US10123530B2 (en) 2012-04-05 2018-11-13 Forschungszentrum Juelich Gmbh Method for treating blood, blood products and organs
WO2013163230A3 (en) * 2012-04-24 2014-01-23 Midori Renewables, Inc. Bio-based polymers and methods of producing thereof
WO2013163230A2 (en) * 2012-04-24 2013-10-31 Midori Renewables, Inc. Bio-based polymers and methods of producing thereof
WO2013173376A1 (en) 2012-05-14 2013-11-21 DePuy Synthes Products, LLC. hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS
WO2014011881A2 (en) 2012-07-11 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US9238845B2 (en) 2012-08-24 2016-01-19 Midori Usa, Inc. Methods of producing sugars from biomass feedstocks
WO2014063035A2 (en) 2012-10-19 2014-04-24 Anthrogenesis Corporation Treatment of pain using amnion derived adherent cells
EP3556215A1 (en) 2012-12-14 2019-10-23 Celularity, Inc. Anoikis resistant placental stem cells and uses thereof
US11130820B2 (en) 2012-12-20 2021-09-28 Celgene Corporation Chimeric antigen receptors
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
EP3882336A1 (en) 2013-03-14 2021-09-22 Celularity Inc. Enhanced placental stem cells and uses thereof
US10967005B2 (en) 2013-03-15 2021-04-06 Celgene Corporation Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
US11806365B2 (en) 2013-03-15 2023-11-07 Celgene Corporation Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
US10293079B2 (en) 2014-05-05 2019-05-21 Sealantis Ltd. Biological adhesives and sealants and methods of using the same
WO2016109668A1 (en) 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
EP3957315A1 (en) 2015-09-15 2022-02-23 Celularity Inc. Treatment of diabetic peripheral neuropathy using placental cells
WO2018009385A1 (en) 2016-07-05 2018-01-11 Janssen Biotech, Inc. Treatment of retinal vascular disease using progenitor cells
WO2018106742A1 (en) 2016-12-05 2018-06-14 Celularity, Inc. Treatment of lymphedema and related conditions using placental adherent cells
WO2019068048A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. Placenta-derived intermediate natural killer (pink) cells for treatment of glioblastoma
WO2019067792A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
GB2594243A (en) * 2020-04-15 2021-10-27 Arterius Ltd A bone cement
CN112175191A (en) * 2020-09-22 2021-01-05 中山大学 Novel crosslinkable degradable multi-block copolymer and preparation method and application thereof
WO2022236187A1 (en) 2021-05-07 2022-11-10 Children's Hospital Los Angeles Methods for making stem cell-derived enteric neural crest cells and their use in enteric neuropathy treatment
CN114249863A (en) * 2022-01-20 2022-03-29 西安交通大学 Hydrogen bond enhanced photocuring hard tissue adhesive and preparation method and use method thereof

Also Published As

Publication number Publication date
KR20020005682A (en) 2002-01-17
ATE448274T1 (en) 2009-11-15
AU760358B2 (en) 2003-05-15
JP2002542349A (en) 2002-12-10
DE60034045D1 (en) 2007-05-03
AU4351800A (en) 2000-11-02
DE60043304D1 (en) 2009-12-24
JP2002542339A (en) 2002-12-10
WO2000062630A1 (en) 2000-10-26
EP1210379B1 (en) 2007-03-21
EP1210379A4 (en) 2002-09-25
US6759485B2 (en) 2004-07-06
US6384105B1 (en) 2002-05-07
DE60026983T2 (en) 2007-01-25
JP2002542352A (en) 2002-12-10
KR100696407B1 (en) 2007-03-19
DE60034045T2 (en) 2007-11-22
KR20010114243A (en) 2001-12-31
US20020177668A1 (en) 2002-11-28
WO2000063263A1 (en) 2000-10-26
ATE357468T1 (en) 2007-04-15
EP1210379A1 (en) 2002-06-05
AU775913B2 (en) 2004-08-19
EP1171006A4 (en) 2002-09-25
DE60026983D1 (en) 2006-05-18
KR100696408B1 (en) 2007-03-19
EP1194463A1 (en) 2002-04-10
EP1171006B1 (en) 2006-03-29
US6306821B1 (en) 2001-10-23
CA2370357A1 (en) 2000-10-26
EP1194463A4 (en) 2002-09-25
AU770579B2 (en) 2004-02-26
AU4349600A (en) 2000-11-02
US6423790B1 (en) 2002-07-23
KR100619611B1 (en) 2006-09-01
CA2370330A1 (en) 2000-10-26
CA2370357C (en) 2007-04-10
WO2000063268A1 (en) 2000-10-26
CA2369758A1 (en) 2000-10-26
EP1194463B1 (en) 2009-11-11
CA2369758C (en) 2007-04-03
KR20010114244A (en) 2001-12-31
JP4644374B2 (en) 2011-03-02
EP1171006A1 (en) 2002-01-16
CA2370330C (en) 2009-01-20
ATE321803T1 (en) 2006-04-15
AU4644700A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
US6384105B1 (en) Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol)
Yaszemski et al. In vitro degradation of a poly (propylene fumarate)-based composite material
He et al. Injectable biodegradable polymer composites based on poly (propylene fumarate) crosslinked with poly (ethylene glycol)-dimethacrylate
EP1664168B1 (en) Hydrogel porogens for fabricating biodegradable scaffolds
US6124373A (en) Bone replacement compound comprising poly(polypropylene fumarate)
US6753358B2 (en) Photocrosslinking of diethyl fumarate/poly(propylene fumarate) biomaterials
US5688900A (en) Absorbable polyalkylene diglycolates
US9255178B2 (en) Photocrosslinkable poly (caprolactone fumarate)
JP5527968B2 (en) Hydrophilic / hydrophobic polymer networks based on poly (caprolactone fumarate), poly (ethylene glycol fumarate) and copolymers thereof
JP2011137166A (en) Crosslinkable, biodegradable, and biocompatible material
Peter et al. Poly (propylene fumarate)
US8715708B2 (en) Cyclic acetal biomaterials

Legal Events

Date Code Title Description
AS Assignment

Owner name: WM. MARSH RICE UNIVERSITY, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HE, SHULIN;MIKOS, ANTONIOS G.;YASZEMSKI, MICHAEL J.;REEL/FRAME:011091/0827

Effective date: 20000816

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:RICE UNIVERSITY;REEL/FRAME:031202/0327

Effective date: 20130910

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20140507